ProPhase Labs, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
ProPhase Labs, Inc. (PRPH) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-01.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2025-04-01
- ProPhase Labs, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- ProPhase Labs, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2023 was $350.00K, a 70.83% decline from fiscal 2022.
- ProPhase Labs, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2022 was $1.20M.
- ProPhase Labs, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2021 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-04-01 |
| 2023-12-31 | $350.00K 10-K · filed 2025-04-01 |
| 2022-12-31 | $1.20M 10-K · filed 2024-03-29 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |